Form 4: HeartSciences Director Granted 15,000 RSUs

HeartSciences Inc. director David R. Wells was granted 15,000 Restricted Stock Units, subject to shareholder approval and performance-based vesting conditions.

Summary

• David R. Wells, a Director of HeartSciences Inc. (HSCS), was granted 15,000 Restricted Stock Units (RSUs).
• The RSUs were granted under the Issuer's 2023 Equity Incentive Plan, as amended, following approval by the Issuer's board of directors.
• Each vested RSU will be settled by the delivery of one share of the Issuer's common stock.
• Vesting of the RSUs is subject to two primary conditions: (i) shareholder approval of any amendment or modification to the Plan, and (ii) time-based vesting over two years, contingent on continuous service.
• Specifically, 50% of the RSUs vest on the one-year anniversary of the grant date, and 1/8th vest on each subsequent quarterly anniversary until fully vested on the two-year anniversary.
• Accelerated vesting of 100% of the RSUs will occur upon a Change of Control (as defined in the Plan) or if the Issuer achieves $250,000 or more in revenue in any fiscal quarter ending after the grant date.

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units to a director, with vesting tied to both time and a significant revenue milestone, aligns the director's interests with shareholder value creation and incentivizes company growth. This is generally a positive mechanism for corporate governance and performance.

Positives

• The RSU grant aligns the director's interests with shareholder value creation through equity ownership.
• Performance-based vesting, tied to achieving $250,000 or more in quarterly revenue, incentivizes company growth and financial performance.
• The time-based vesting schedule encourages long-term commitment and continuous service from the director.

Risks

• The vesting of RSUs is contingent on shareholder approval of an amendment or modification to the 2023 Equity Incentive Plan, which could potentially not be granted.
• The accelerated vesting condition tied to revenue achievement ($250,000 in a fiscal quarter) introduces a performance risk, as this target may not be met.

Future Outlook

The RSU grant, with its performance-based vesting condition tied to a specific revenue target, indicates an incentive for future company growth and financial achievement. The time-based vesting also suggests an expectation of continued service from the director.

Industry Context

This filing is a standard insider transaction report and does not provide specific industry context or trends.

Comparison to Industry Standards

• N/A. The filing does not provide data for comparison to global benchmarks or specific comparable companies/projects.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aims to align the director's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees: While not directly impacting all employees, the incentive structure for a director can set a precedent for performance-based compensation within the company.

Next Steps

• Shareholder approval of the amendment or modification to the 2023 Equity Incentive Plan is required for the RSUs to vest.
• The company will need to achieve the specified revenue target or experience a Change of Control for accelerated vesting.
• The director must maintain continuous service on the Board through the applicable vesting dates for time-based vesting.

Key Dates

Keywords

HeartSciences Inc., HSCS, Restricted Stock Units, RSU, Equity Incentive Plan, Director Compensation, Insider Transaction, Vesting Conditions, Corporate Governance, Performance Incentives